Literature DB >> 3234441

Nephrotoxicity associated with ifosfamide.

J Smeitink1, M Verreussel, C Schröder, R Lippens.   

Abstract

Three patients developed a Fanconi syndrome with impairment of glomerular function (endogenous creatinine clearance 30-60 ml/min per 1.73 m2) during and/or after treatment with ifosfamide according to the SIOP-MMT 84 protocol in which ifosfamide was given in a dose of 3000 mg/m2 every 4 weeks over a 10-month period. The need for early substitution therapy in patients with the Fanconi syndrome is stressed. The renal lesions in our patients were irreversible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234441     DOI: 10.1007/bf00445929

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Urinary excretion of calcium and magnesium in children.

Authors:  S Ghazali; T M Barratt
Journal:  Arch Dis Child       Date:  1974-02       Impact factor: 3.791

2.  [Toxic-allergic lung edema following cyclophosphamide and ifosfamide therapy. Case report].

Authors:  A Kehl; M Bergholz; H W von Heyden; G A Nagel
Journal:  Onkologie       Date:  1983-04

Review 3.  Nephrological complications of cancer therapy.

Authors:  W Kreusser; R Herrmann; W Tschöpe; E Ritz
Journal:  Contrib Nephrol       Date:  1982       Impact factor: 1.580

4.  Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.

Authors:  M E Heim; R Fiene; E Schick; E Wolpert; W Queisser
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

5.  Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.

Authors:  G Sangster; S B Kaye; K C Calman; J F Dalton
Journal:  Eur J Cancer Clin Oncol       Date:  1984-03

Review 6.  Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.

Authors:  F Ries; J Klastersky
Journal:  Am J Kidney Dis       Date:  1986-11       Impact factor: 8.860

7.  Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.

Authors:  P Hilgard; H Burkert
Journal:  Eur J Cancer Clin Oncol       Date:  1984-11

8.  Renal threshold phosphate concentration (TmPO4/GFR).

Authors:  K Kruse; U Kracht; G Göpfert
Journal:  Arch Dis Child       Date:  1982-03       Impact factor: 3.791

9.  DDAVP test for assessment of renal concentrating capacity in infants and children.

Authors:  L Monnens; Y Smulders; H van Lier; T de Boo
Journal:  Nephron       Date:  1981       Impact factor: 2.847

  9 in total
  17 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Cancer therapies and bone health.

Authors:  Mimi I Hu; Huifang Lu; Robert F Gagel
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

4.  Hypophosphatemic rickets after ifosfamide treatment.

Authors:  R A Newbury-Ecob; P R Barbor
Journal:  BMJ       Date:  1989-07-22

Review 5.  Cytostatics--induced tubular toxicity.

Authors:  M Brandis; K von der Hardt; R B Zimmerhackl; M Mohrmann; J Leititis
Journal:  Clin Investig       Date:  1993-10

6.  Partial and complete de Toni-Debré-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy.

Authors:  R Rossi; J H Ehrich
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 8.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamide.

Authors:  J de Schepper; S Hachimi-Idrissi; O Louis; R Maurus; J Otten
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

10.  Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Authors:  V Gilard; M C Malet-Martino; M de Forni; U Niemeyer; J C Ader; R Martino
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.